{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T02:14:07Z","timestamp":1780107247201,"version":"3.54.0"},"reference-count":19,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100013873","name":"Government of Ontario","doi-asserted-by":"publisher","award":["P.AO.075"],"award-info":[{"award-number":["P.AO.075"]}],"id":[{"id":"10.13039\/100013873","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013873","name":"Government of Ontario","doi-asserted-by":"publisher","award":["P.OCT.051"],"award-info":[{"award-number":["P.OCT.051"]}],"id":[{"id":"10.13039\/100013873","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1136\/ijgc-2020-001849","type":"journal-article","created":{"date-parts":[[2020,9,30]],"date-time":"2020-09-30T17:15:35Z","timestamp":1601486135000},"page":"139-143","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Across barriers: poly ADP-ribose polymerase inhibitors beyond progression in high grade serous ovarian cancer with brain metastases"],"prefix":"10.1016","volume":"31","clinical-trial-number":[{"clinical-trial-number":"nct02906943","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Lawrence","family":"Kasherman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7166-9762","authenticated-orcid":false,"given":"Ainhoa","family":"Madariaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjan","family":"Rouzbahman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kieran","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Shultz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracy","family":"Stockley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit M","family":"Oza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ijgc-2020-001849_bb0010","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdy285.154","article-title":"Brain metastases in primary ovarian cancer: real-world data","volume":"29","author":"Ratner","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1136\/ijgc-2020-001849_bb0015","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.ygyno.2016.09.025","article-title":"Brain metastases in patients with EOC: clinico-pathological and prognostic factors. A multicentric retrospective analysis from the MITO group (MITO 19)","volume":"143","author":"Marchetti","year":"2016","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2020-001849_bb0020","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.3892\/ol.2017.5621","article-title":"Stereotactic radiosurgery for brain metastasis from gynecological malignancies","volume":"13","author":"Kasper","year":"2017","journal-title":"Oncol Lett"},{"key":"10.1136\/ijgc-2020-001849_bb0025","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s11060-017-2459-z","article-title":"Next-generation sequencing-based genomic profiling of brain metastases of primary ovarian cancer identifies high number of BRCA-mutations","volume":"133","author":"Balendran","year":"2017","journal-title":"J Neurooncol"},{"key":"10.1136\/ijgc-2020-001849_bb0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2019.03.032","article-title":"Integrative immunologic and genomic characterization of brain metastasis from ovarian\/peritoneal cancer","volume":"215","author":"Choi","year":"2019","journal-title":"Pathol Res Pract"},{"key":"10.1136\/ijgc-2020-001849_bb0035","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.ygyno.2019.05.004","article-title":"Brain metastasis in epithelial ovarian cancer by BRCA1\/2 mutation status","volume":"154","author":"Stasenko","year":"2019","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2020-001849_bb0040","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.ygyno.2016.04.030","article-title":"Clinicopathologic characteristics and survival of patients with gynecologic malignancies metastatic to the brain","volume":"142","author":"Divine","year":"2016","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2020-001849_bb0045","doi-asserted-by":"crossref","DOI":"10.1186\/s13073-018-0590-x","article-title":"Landscape of genomic alterations in high-grade serous ovarian cancer from exceptional long- and short-term survivors","volume":"10","author":"Yang","year":"2018","journal-title":"Genome Med"},{"key":"10.1136\/ijgc-2020-001849_bb0050","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1136\/ijgc-2020-001288","article-title":"Manage wisely: poly (ADP-ribose) polymerase inhibitor (PARPi) treatment and adverse events","volume":"30","author":"Madariaga","year":"2020","journal-title":"Int J Gynecol Cancer"},{"key":"10.1136\/ijgc-2020-001849_bb0055","doi-asserted-by":"crossref","DOI":"10.1158\/1535-7163.TARG-15-B168","article-title":"Abstract B168: the PARP inhibitor, niraparib, crosses the blood brain barrier in rodents and is efficacious in a BRCA2-mutant intracranial tumor model","volume":"14","author":"Mikule","year":"2015","journal-title":"Mol Cancer Ther"},{"key":"10.1136\/ijgc-2020-001849_bb0060","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1038\/bjc.2014.91","article-title":"Tumour cell retention of rucaparib, sustained PARP inhibition and efficacy of weekly as well as daily schedules","volume":"110","author":"Murray","year":"2014","journal-title":"Br J Cancer"},{"key":"10.1136\/ijgc-2020-001849_bb0065","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1038\/nrclinonc.2011.42","article-title":"Treatment with olaparib in a patient with PTEN-deficient endometrioid endometrial cancer","volume":"8","author":"Forster","year":"2011","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1136\/ijgc-2020-001849_bb0070","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2019-230738","article-title":"Niraparib as maintenance therapy in a patient with ovarian cancer and brain metastases","volume":"12","author":"Gray","year":"2019","journal-title":"BMJ Case Rep"},{"key":"10.1136\/ijgc-2020-001849_bb0075","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.gore.2016.10.004","article-title":"Olaparib treatment for BRCA-mutant ovarian cancer with leptomeningeal disease","volume":"18","author":"Bangham","year":"2016","journal-title":"Gynecol Oncol Rep"},{"key":"10.1136\/ijgc-2020-001849_bb0080","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1111\/jog.13851","article-title":"Durable response by olaparib for a Japanese patient with primary peritoneal cancer with multiple brain metastases: a case report","volume":"45","author":"Sakamoto","year":"2019","journal-title":"J Obstet Gynaecol Res"},{"key":"10.1136\/ijgc-2020-001849_bb0085","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1056\/NEJMoa1802905","article-title":"Talazoparib in patients with advanced breast cancer and a germline BRCA mutation","volume":"379","author":"Litton","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1136\/ijgc-2020-001849_bb0090","doi-asserted-by":"crossref","DOI":"10.1093\/neuonc\/noaa104","article-title":"Pharmacokinetics, safety and tolerability of olaparib and temozolomide for recurrent glioblastoma: results of the phase I OPARATIC trial","author":"Hanna","year":"2020","journal-title":"Neuro Oncol"},{"key":"10.1136\/ijgc-2020-001849_bb0095","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2018.00208","article-title":"Management of brain metastases in epidermal growth factor receptor mutant non-small-cell lung cancer","volume":"8","author":"Kelly","year":"2018","journal-title":"Front Oncol"},{"key":"10.1136\/ijgc-2020-001849_bb0100","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.ijrobp.2018.03.058","article-title":"Stereotactic body radiation therapy for oligometastatic ovarian cancer: a step toward a drug holiday","volume":"101","author":"Lazzari","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24026069?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24026069?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ijgc-2020-001849","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T22:19:48Z","timestamp":1753222788000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X24026069"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["S1048891X24026069"],"URL":"https:\/\/doi.org\/10.1136\/ijgc-2020-001849","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Across barriers: poly ADP-ribose polymerase inhibitors beyond progression in high grade serous ovarian cancer with brain metastases","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ijgc-2020-001849","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 IGCS and ESGO 2021. No commercial re-use. See rights and permissions. Published by BMJ.","name":"copyright","label":"Copyright"}]}}